

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human IL-4 in Western blots. In Western blots, no cross-reactivity with recombinant mouse IL-4, recombinant porcine IL-4, recombinant cotton rat IL-4, recombinant rat IL-4, or recombinant human IL-13 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 34019
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human IL-4 His25-Ser153 Accession # P05112
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Human IL-4 (Catalog # 204-IL)
Neutralization		Measured by its ability to neutralize IL-4-induced proliferation in the TF-1 human erythroleukemic cell line. Kitamura, T. <i>et al.</i> (1989) <i>J. Cell Physiol.</i> 140 :323. The Neutralization Dose (ND ₅₀) is typically 0.5-1.5 µg/mL in the presence of 0.5 ng/mL Recombinant Human IL-4.

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13-18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1-3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four α -helix structure (4). Human IL-4 is synthesized with a 24 aa signal sequence. Alternate splicing generates an isoform with a 16 aa internal deletion. Mature human IL-4 shares 55%, 39%, and 43% aa sequence identity with bovine, mouse, and rat IL-4, respectively. Human, mouse, and rat IL-4 are species-specific in their activities (5-7). IL-4 exerts its effects through two receptor complexes (8, 9). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R α and the common γ chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and -21). The type II receptor on non-hematopoietic cells consists of IL-4 R α and IL-13 R α 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4⁺ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgG4 and IgE in human B cells, acquisition of the Th2 phenotype by naive CD4⁺ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (10-13). IL-4 plays a dominant role in the development of allergic inflammation and asthma (12, 14).

References:

1. Benczik, M. and S.L. Gaffen (2004) *Immunol. Invest.* **33**:109.
2. Chomarat, P. and J. Banchereau (1998) *Int. Rev. Immunol.* **17**:1.
3. Yokota, T. *et al.* (1986) *Proc. Natl. Acad. Sci. USA* **83**:5894.
4. Redfield, C. *et al.* (1991) *Biochemistry* **30**:11029.
5. Ramirez, F. *et al.* (1988) *J. Immunol. Meth.* **221**:141.
6. Leitenberg, D. and T.L. Feldbush (1988) *Cell. Immunol.* **111**:451.
7. Mosman, T.R. *et al.* (1987) *J. Immunol.* **138**:1813.
8. Mueller, T.D. *et al.* (2002) *Biochim. Biophys. Acta* **1592**:237.
9. Nelms, K. *et al.* (1999) *Annu. Rev. Immunol.* **17**:701.
10. Paludan, S.R. (1998) *Scand. J. Immunol.* **48**:459.
11. Corthay, A. (2006) *Scand. J. Immunol.* **64**:93.
12. Ryan, J.J. *et al.* (2007) *Crit. Rev. Immunol.* **27**:15.
13. Grone, A. (2002) *Vet. Immunol. Immunopathol.* **88**:1.
14. Rosenberg, H.F. *et al.* (2007) *J. Allergy Clin. Immunol.* **119**:1303.